Pages that link to "Q34656455"
Jump to navigation
Jump to search
The following pages link to (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties (Q34656455):
Displaying 50 items.
- Tapentadol hydrochloride: A novel analgesic (Q24629365) (← links)
- Role of Tapentadol Immediate Release (Nucynta) in the Management Of Moderate-to-Severe Pain (Q24632728) (← links)
- A new drug design targeting the adenosinergic system for Huntington's disease (Q27335053) (← links)
- Recent advances in postoperative pain management (Q27692684) (← links)
- Mechanistic and functional differentiation of tapentadol and tramadol (Q28268772) (← links)
- The use of opioids in fibromyalgia (Q28305020) (← links)
- A Randomized Controlled Trial on the Effect of Tapentadol and Morphine on Conditioned Pain Modulation in Healthy Volunteers (Q28548331) (← links)
- Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis (Q30830216) (← links)
- Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data (Q31128284) (← links)
- Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR. (Q33652919) (← links)
- Successful use of stellate ganglion block and a new centrally acting analgesic with dual mode of action in a resistant temporomandibular joint pain (Q33691651) (← links)
- Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release (Q33775071) (← links)
- Spinal cord transection-induced allodynia in rats--behavioral, physiopathological and pharmacological characterization (Q33897359) (← links)
- Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial. (Q33938745) (← links)
- Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists (Q34063701) (← links)
- Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs (Q34158082) (← links)
- The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice (Q34158846) (← links)
- Differences between opioids: pharmacological, experimental, clinical and economical perspectives (Q34272502) (← links)
- Tapentadol immediate release: a new treatment option for acute pain management (Q34418280) (← links)
- Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse (Q34512974) (← links)
- Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies (Q34615173) (← links)
- Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial (Q34625849) (← links)
- Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor (Q34628322) (← links)
- Pharmacology update: tapentadol for neuropathic pain (Q34635669) (← links)
- Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies (Q34636179) (← links)
- μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons (Q34939720) (← links)
- Tapentadol extended release in the management of peripheral diabetic neuropathic pain (Q34982228) (← links)
- Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model (Q35009932) (← links)
- Emerging concepts in post-operative pain management (Q35020309) (← links)
- Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? (Q35178751) (← links)
- Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting (Q35178875) (← links)
- Anesthetic Routines: The Anesthesiologist's Role in GI Recovery and Postoperative Ileus (Q35202119) (← links)
- Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain. (Q35752535) (← links)
- Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study (Q36085061) (← links)
- Tapentadol for Cancer Pain Management: A Narrative Review (Q36248445) (← links)
- Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents (Q36480105) (← links)
- Assessment of a formulation designed to be crush-resistant in prescription opioid abusers (Q36845718) (← links)
- A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers (Q36878938) (← links)
- Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users (Q36930408) (← links)
- Comparison of tapentadol with tramadol for analgesia after cardiac surgery (Q36939600) (← links)
- Probable Tapentadol-Associated Serotonin Syndrome After Overdose (Q36977203) (← links)
- Patient considerations in the use of tapentadol for moderate to severe pain (Q36991981) (← links)
- Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain (Q37115472) (← links)
- Diversion and Illicit Sale of Extended Release Tapentadol in the United States (Q37154667) (← links)
- Preclinical and early clinical investigations related to monoaminergic pain modulation (Q37374356) (← links)
- The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. (Q37395994) (← links)
- Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride (Q37420677) (← links)
- Role of preemptive tapentadol in reduction of postoperative analgesic requirements after laparoscopic cholecystectomy. (Q37533877) (← links)
- Tapentadol immediate release for the relief of moderate-to-severe acute pain (Q37606489) (← links)
- Variable use of opioid pharmacotherapy for chronic noncancer pain in Europe: causes and consequences (Q37641344) (← links)